Meeting
2019 ASCO Annual Meeting
KEYNOTE-826: a phase 3, randomized, double-blind, placebo-controlled study of pembrolizumab plus chemotherapy for first-line treatment of persistent, recurrent, or metastatic cervical cancer.
Authors
Ronnie Shapira-Frommer
Sheba Medical Center, Ramat-Gan, Israel
Ronnie Shapira-Frommer , Jerome Alexandre , Bradley Monk , Tanja N. Fehm , Nicoletta Colombo , Maria V. Caceres , Kosei Hasegawa , Coraline Dubot , Jerry Jing Li , Karen Stein , Stephen Michael Keefe , Krishnansu Sujata Tewari
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gynecologic Cancer
Track
Gynecologic Cancer
Sub Track
Cervical Cancer
Clinical Trial Registration Number
NCT03635567
Citation
J Clin Oncol 37, 2019 (suppl; abstr TPS5595)
DOI
10.1200/JCO.2019.37.15_suppl.TPS5595
Abstract #
TPS5595
Poster Bd #
417b
Abstract Disclosures
Similar Posters
First Author: Ana Oaknin
Poster
2023 ASCO Annual Meeting
The efficacy and safety of tislelizumab plus bevacizumab and chemotherapy as first line therapy in patients with persistent, recurrent, or metastatic cervical cancer: A multicenter, phase II study.
First Author: Jianqing Zhu
Poster
2022 ASCO Annual Meeting
A randomized, double-blind, phase 3 trial of MK-7684A plus chemotherapy versus pembrolizumab plus chemotherapy as first-line therapy for metastatic non–small cell lung cancer (NSCLC): KeyVibe-007.
First Author: Marina Chiara Garassino
Poster
2019 ASCO Annual Meeting
ENGOT-OV43/KEYLYNK-001: A phase III, randomized, double-blind, active- and placebo-controlled study of pembrolizumab plus chemotherapy with olaparib maintenance for first-line treatment of BRCA-nonmutated advanced epithelial ovarian cancer.
First Author: Ignace Vergote